Growth hormone deficiency

Versartis: XTEN Data From Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for Increasing Serum Half-Life of Protein Therapeutics

Market Wire (Free subscription) | 11/15/2009

REDWOOD CITY, CA and MOUNTAIN VIEW, CA (MARKET WIRE) Amunix, Inc. and Versartis, Inc. announced today that the scientific journal Nature Biotechnology has published a comprehensive paper entitled "A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner." The paper (http://dx.doi.org/10.1038/nbt.1588) describes the design of Amunix's polypeptide...

AACE Issues New Medical Guidelines For Proper And Ethical Use Of Growth Hormone

Medical News Today (Free subscription) | 11/04/2009

The American Association of Clinical Endocrinologists (AACE) released new medical guidelines for the accurate diagnosis and effective ethical treatment of growth hormone deficiency in affected patients. Growth hormone replacement therapy has proven useful for children and adults with scientifically proven growth hormone deficiency.

AACE Issues New Medical Guidelines for Proper and Ethical Use of Growth Hormone

PR News Wire (Free subscription) | 11/03/2009

JACKSONVILLE, Fla., Nov. 3 /PRNewswire-USNewswire/ -- Today the American Association of Clinical Endocrinologists (AACE) released new medical guidelines for the accurate diagnosis and effective ethical treatment of growth hormone deficiency in affected patients.

Growth Hormone Deficiency Therapy Area Pipeline Report

aarkstore | 10/29/2009

Growth Hormone Deficiency Therapy Area Pipeline Report contains detailed information on the growth hormone deficiency drug pipeline. This report provides insight into the pipeline status of growth hormone deficiency drugs by company and by stage as well as a summary of the latest news and developments in this area. Scope of the report: Therapy Area Pipeline Report provides the user with real detail

"Undervalued" Theratechnologies Inc. (OTC:THTCF) (TSE:TH) (TOR,NAB:TH,THTCF)

BAYSTREET NEWSWIRE (Free subscription) | 10/22/2009

GMP securities called the stock undervalued…” Dow Jones, Oct. 6 2009. Theratechnologies Inc. is a biopharmaceutical company that discovers novel therapeutic products for development and commercialization. These products target unmet medical needs in commercially attractive specialty markets. The Syndrome Y ou have been diagnosed with HIV. As a result of your HIV therapy and disease, you...

Dalton School Kids Doped Up on Growth Hormones

Gothamist (Free subscription) | 10/19/2009

Forget about swine flu, the kids at Dalton are suffering from shortness . The fancy pants Upper East Side school is filled with boys battling the problem. The cause: being a child. The cure: parents armed with growth hormones. The NY Post reports on a few of the kids — one, Jeffrey, went on the Humatrope hormone at age 10. In just five years he shot up from 4'1" to 5'7" ... and still...

AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency

PR News Wire (Free subscription) | 10/19/2009

QUEBEC CITY, Oct. 19 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it has initiated activities intended to complete the clinical development of the growth hormone secretagogue (GHS) / ghrelin agonist compound macimorelin (AEZS-130) which could be the...

Growth Hormone Deficiency Therapy Area Pipeline Report

aarkstore | 09/24/2009

Growth Hormone Deficiency Therapy Area Pipeline Report contains detailed information on the growth hormone deficiency drug pipeline. This report provides insight into the pipeline status of growth hormone deficiency drugs by company and by stage as well as a summary of the latest news and developments in this area. Scope of the report: Therapy Area Pipeline Report provides the user with real detail

Altus Pharma to Shut Doors

Xconomy (Free subscription) | 09/15/2009

Waltham, MA-based Altus Pharmaceuticals, a developer of protein-based drugs, revealed in an SEC filing yesterday that it decided last week “wind down” the company’s operations. The company (NASDAQ:ALTU) is also ending a mid-stage clinical trial to test its growth hormone deficiency drug ALTU-238 in children. The firm plans to let go “substantially all” of [...]

Research and Markets: Growth Hormone Deficiency Therapy Area Pipeline Report

Business Wire (Free subscription) | 09/09/2009

What Is HGH?

Insparenting (Free subscription) | 08/31/2009

HGH or human growth hormone is a Protein Poly-peptide hormone. It stimulates growth and cell reproduction and regeneration in humans and other animals. Growth hormone is used clinically to treat children’s growth disorders and adult growth hormone deficiency. In recent years, replacement therapies with human growth hormones (HGH) have become popular in the battle against [...]

Miami drug wholesaler convicted of conspiring to divert growth hormones

Joseph Kim, MD, MPH (Free subscription) | 08/10/2009

Here's the latest press release: MIAMI PRESCRIPTION DRUG WHOLESALER CONVICTED Jeffrey H. Sloman, Acting United States Attorney for the Southern District of Florida, and David W. Bourne, Special Agent in Charge, U.S. Food and Drug Administration (FDA), Office of Criminal Investigations, Miami Field Office, announced that after a two week trial before U.S. District Judge Alan S. Gold, a jury convicted...

Troubled Altus to run out of cash soon

Fiercebiotech (Free subscription) | 08/05/2009

On announcing its quarterly results today, Altus Pharmaceuticals said the company will not be able to fund its operations beyond Q3 if it's unable to secure cash soon. This comes after the Waltham, MA-based developer cut 70 percent of its staff and reduced development operations in a restructuring that focused its resources on ALTU-238, a growth hormone deficiency treatment currently in Phase II development....

Inhaled Growth Hormone Safe For Children Deficient In This Key Protein, Study Suggests

Science Daily (Free subscription) | 06/26/2009

Endocrinologists have found that inhaled growth hormone is well tolerated by children with growth hormone deficiency and that this easy-to-use method can safely deliver GH to the blood stream. This first pediatric study of administering GH through the lungs may also help researchers interested in using this convenient method for effectively delivering other types of medications to children.

• See the 4 articles on the same subject

Altus Pharmaceuticals Reports Dosing First Patient In A Phase 2 Trial Of ALTU-238 For Pediatric Growth Hormone Deficiency

Medical News Today (Free subscription) | 06/12/2009

Altus Pharmaceuticals Inc. (NASDAQ: ALTU) announced that patient dosing in its Phase 2 trial for ALTU-238 in growth hormone deficiency pediatric subjects began on June 2, 2009. ALTU-238 is a long-acting, extended-release formulation of recombinant human growth hormone (rhGH, somatropin), which is being developed utilizing Altus' proprietary protein crystallization technology.

Growth Hormone Deficiency Therapy Area Pipeline Report

aarkstore | 10/29/2009

Growth Hormone Deficiency Therapy Area Pipeline Report contains detailed information on the growth hormone deficiency drug pipeline. This report provides insight into the pipeline status of growth hormone deficiency drugs by company and by stage as well as a summary of the latest news and developments in this area. Scope of the report: Therapy Area Pipeline Report provides the user with real detail...

Growth Hormone Deficiency Therapy Area Pipeline Report

aarkstore | 09/24/2009

Growth Hormone Deficiency Therapy Area Pipeline Report contains detailed information on the growth hormone deficiency drug pipeline. This report provides insight into the pipeline status of growth hormone deficiency drugs by company and by stage as well as a summary of the latest news and developments in this area. Scope of the report: Therapy Area Pipeline Report provides the user with real detail...